Open report — full analysis, no account required.

Sign up to generate reports and read filings that aren't on the open list.

Sign up free

Get notified when LLY files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NYSE: LLY ELI LILLY & Co 8-K

Eli Lilly reports Q4 and full-year 2025 financial results

Filed February 4, 2026 · Period ending February 4, 2026 · ~1 min read

1 key change 1 high relevance 1 section

Key Changes

  • high

    Company disclosed fourth quarter and full-year 2025 earnings through press release dated February 4, 2026, with detailed financial metrics in attached exhibit.

    Item 2.02 — Results of Operations and Financial Condition verify on EDGAR →

Summary

Eli Lilly filed an 8-K to announce its fourth quarter and full-year 2025 financial results through a press release dated February 4, 2026. This is a standard quarterly earnings disclosure required under Item 2.02, where companies report operating results and financial condition to investors. The actual performance metrics, revenue figures, earnings per share, and management's discussion of results are contained in the attached press release exhibit.

For retail investors, this filing signals the availability of Lilly's latest financial performance data. The key action item is to review the full press release (Exhibit 99.1) for specifics on revenue growth, profitability trends, and forward guidance. Pay particular attention to performance of key drug franchises and any commentary on pipeline developments or market conditions that could affect 2026 outlook.

Section-by-Section Diff

Event · Item 2.02 — Results of Operations and Financial Condition

~100 words

Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.

1 Added
Added Q4 and FY 2025 earnings announcement high

Added in current filing · verify on EDGAR →

Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated February 4, 2026, announcing the financial results of Eli Lilly and Company for the quarter and year ended December 31, 2025.

Eli Lilly disclosed its financial results for the fourth quarter and full year ended December 31, 2025, through a press release dated February 4, 2026. The actual financial metrics, revenue figures, earnings per share, and management commentary would be contained in the referenced Exhibit 99.1 press release, which is not included in the 8-K body text provided here.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · Jun 17, 2026 · How we verify